Results 71 to 80 of about 1,981 (114)
Some of the next articles are maybe not open access.
Treatment of Stable Angina Pectoris
American Journal of Therapeutics, 2011Management of stable angina pectoris includes antianginal medications, medications to prevent progression of atherosclerosis, and aggressive treatment of causative risk factors. Antianginal medications commonly used include nitrates, beta-blockers, calcium channel blockers, and ranolazine. Antiplatelet agents, statins, and angiotensin-converting enzyme
Chandrasekar, Palaniswamy +1 more
openaire +2 more sources
Statins in Stable Angina Pectoris
Current Pharmaceutical Design, 2018Background: Stable angina is a debilitating and progressive disease caused by narrowing of the coronary arteries, which in turn affects cardiac perfusion. Statins have a well-established role, modifying symptoms and progression of the disease not only through lipid lowering, but also through pleiotropic effects.
Adam, Ioannou +10 more
openaire +2 more sources
The Prognosis in Stable and Unstable Angina
Cardiology Clinics, 1991The average annual mortality in unselected patients with chronic stable angina is 4%. Mortality is increased in male patients and in patients who have risk factors such as hypertension, previous MI, or abnormal ECGs. We do not routinely recommend cardiac catheterization in the initial management of patients with stable angina unless the patient ...
T C, Hilton, B R, Chaitman
openaire +2 more sources
Ranolazine for chronic stable angina
The Lancet, 2008Ranolazine is a new and unique antianginal drug that has been approved for the treatment of chronic stable angina pectoris. The drug is administered as a sustained-release formulation. Although the drug's mechanism of action has not been fully elucidated, current thinking is that ranolazine, a selective inhibitor of late sodium influx, attenuates the ...
David T, Nash, Stephen D, Nash
openaire +2 more sources
Optimal Treatment of Stable Angina
Cardiology, 2008Angina pectoris due to coronary artery disease is a common manifestation of myocardial ischemia. Reduction of oxygen demand (β-blockers) and relief of coronary vasoconstriction (calcium blocker or nitrate) are additive approaches to controlling ischemia.
openaire +2 more sources
Management of Chronic Stable Angina
Critical Care Nursing Clinics of North America, 2017Chronic stable angina (CSA) is a symptomatic problem that is precipitated by ischemic heart disease. CSA is diagnosed when symptoms are present for at least 2 months without changes in severity, character, or triggering circumstances. This article is a summary of current treatment strategies aimed to prevent progression of atherosclerosis, and ...
openaire +2 more sources
Advances in the Management of Stable Angina
Journal of Managed Care Pharmacy, 2006To describe the approved uses, pharmacology, pharmacodynamics, pharmacokinetics, efficacy, safety, and place in therapy of ranolazine, the first new antianginal drug therapy introduced in more than 20 years for the treatment of chronic angina.The mechanism of action of ranolazine is unknown, but it may involve inhibition of the late sodium current in ...
openaire +2 more sources
Pathophysiology of Stable Angina Pectoris
Cardiology Clinics, 1991The pathophysiology of stable angina is discussed with respect to anatomic substrate, coronary and systemic hemodynamic mechanisms, the dynamic nature of coronary artery stenoses, and determinants of myocardial oxygen consumption. Cellular mechanisms involved in ischemia and the transduction of these changes into angina are also reviewed.
openaire +2 more sources
Trimetazidine for stable angina pectoris
Expert Opinion on Pharmacotherapy, 2001Stable angina pectoris, a symptom of coronary heart disease (CHD), manifests as stress-induced ischaemic episodes resulting in severe chest pain. Therapeutic aims are to improve quality of life by decreasing anginal attacks and to prevent myocardial infarction (MI) and death.
openaire +2 more sources